Navigation Links
Mayo Clinic Study Using Structural MRI May Help Accurately Diagnose Dementia Patients
Date:7/11/2009

ROCHESTER, Minn., July 11 /PRNewswire-USNewswire/ -- A new Mayo Clinic study may help physicians differentially diagnose three common neurodegenerative disorders in the future. The study will be presented at the Alzheimer's Association International Conference on Alzheimer's Disease on July 11 in Vienna.

In this study, Mayo Clinic researchers developed a framework for MRI-based differential diagnosis of three common neurodegenerative disorders: Alzheimer's disease, frontotemporal lobar degeneration, and Lewy body disease using Structural MRI. Currently, examination of the brain at autopsy is the only way to confirm with certainty that a patient had a specific form of dementia. The framework, which is called "STructural Abnormality iNDex" or STAND-Map, shows promise in accurately diagnosing dementia patients while they are alive. The rationale is that if each neurodegenerative disorder can be associated with a unique pattern of atrophy specific on MRI, then it may be possible to differentially diagnose new patients. The study looked at 90 patients from the Mayo Clinic database who were confirmed to have only a single dementia pathology and also underwent an MRI at the time of clinical diagnosis of dementia. Using the STAND-Map framework, researchers predicted an accurate pathological diagnosis 75 to 80 percent of the time.

"The STAND-Map framework might have great potential in early diagnosis of dementia patients," says Prashanthi Vemuri, Ph.D., a senior research fellow at the Mayo Clinic aging and dementia imaging research lab and lead author of the study. "The next step would be to test the framework on a larger population to see if we can replicate these results and improve the accuracy level we achieved in this proof of concept study. In turn, this may lead to better treatment options for dementia patients."

The senior author of this Mayo Clinic research study is Clifford Jack, M.D. Other members included Kejal Kantarci, M.D.; Matthew L. Senjem; Jeffrey Gunter; Jennifer Whitwell, Ph.D.; Keith Josephs, M.D.; David Knopman, M.D.; Bradley Boeve, M.D.; Tanis Ferman, Ph.D.; Dennis Dickson, M.D.; and Ronald Petersen, Ph.D., M.D.

This work was supported in part by National Institutes of Health (NIH) grants, Robert H. Smith Family Foundation Research Fellowship, Alexander Family Alzheimer's Disease Research Professorship.

About Mayo Clinic

Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy of "the needs of the patient come first." More than 3,300 physicians, scientists and researchers and 46,000 allied health staff work at Mayo Clinic, which has sites in Rochester, Minn; Jacksonville, Fla; and Scottsdale/Phoenix, Ariz. Collectively, the three locations treat more than half a million people each year. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. For information about research and education visit www.mayo.edu. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories.


'/>"/>
SOURCE Mayo Clinic
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Renowned, Cleveland Clinic Foundation, Orthopaedic Sports Medicine Surgeon, John Bergfeld, MD, Inducted into Sports Medicine Hall of Fame
2. Health clinic conditions may be to blame for decrease in primary care physicians
3. Insite Security Partners With WorldClinic to Offer Global Medical Support to Clients
4. AlphaRx Reports Positive Preclinical Data on GAI-122 Against Liver Disease
5. Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment
6. Vancouver Fertility Acupuncture Clinic Announces New Fellows of the American Board of Oriental Reproductive Medicine
7. June 2009 Mayo Clinic Health Letter Highlights Probiotics, Carotid Artery and Breast Cancer Treatments
8. Can a Contact Lens Cure Nearsightedness? Five-Year Clinical Study Testing Corneal Reshaping Therapy as Possible Method to Arrest Myopia
9. ERT Launches New Online Gateway to Improve Cardiac Safety in Clinical Trials
10. Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development
11. NCI Renews Mayo Clinic Cancer Center Support Grant, Extends Comprehensive Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Kwalu, a ... year in a row; they are the recipient of the prestigious “Best Overall ... on the award at Design Connections 2017. Top A&D professionals from leading firms, ...
(Date:3/27/2017)... Switzerland (PRWEB) , ... March 27, 2017 , ... ... food industry. Conventional sodium testing methods are complicated and require expert user knowledge. ... a new analytical method dedicated to the simplified, yet highly accurate, determination of ...
(Date:3/27/2017)... Clearwater, Fla. (PRWEB) , ... March 27, 2017 , ... ... (1) and the number of homeowners utilizing DIY and unlicensed contractors for renovations is ... bathroom remodel or replacement project in 2015, and of those, 42% failed to use ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... contaminated soil, dredged material, and hazardous and non-hazardous materials announced today the acquisition ... This acquisition will add four additional processing facilities and a vast array ...
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business Management ... . The annual awards, now in their 12th year, are among the most prestigious ... , In 2016, the awards were retooled to recognize achievements in both large budget ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... BOSTON , March 27, 2017 ... pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), ... commercialization of innovative therapies based upon tetracycline chemistry, ... sarecycline for the treatment of moderate to severe ... Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived ...
(Date:3/27/2017)... NEW YORK , March 27, 2017 ... and technology platform for value-based precision medicine, ... multi-year collaboration with Novartis Pharmaceuticals Corporation to ... breast cancer patients. As part ... the previous announced collaboration entered into January ...
(Date:3/27/2017)... 2017 Arena Pharmaceuticals, Inc. (NASDAQ: ... small molecule drugs across multiple therapeutic areas, today announced that ... will present a corporate update at the 16th Annual Needham ... conference will take place April 4-5, 2017 at the Westin ... , NY.  A live audio webcast of ...
Breaking Medicine Technology: